Evidence map›Paper›PMID 37871223›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Expression signature of human endogenous retroviruses in chronic lymphocytic leukemia.

Alessandro La Ferlita, Giovanni Nigita, Liudmyla Tsyba, Alexey Palamarchuk, Salvatore Alaimo, Alfredo Pulvirenti, Veronica Balatti, Laura Rassenti, Philip N Tsichlis, Thomas Kipps and 2 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandro La Ferlita *Department of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Giovanni Nigita *Department of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Liudmyla TsybaDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Alexey PalamarchukDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Salvatore AlaimoDepartment of Clinical and Experimental Medicine, Bioinformatics Unit, University of Catania, Catania 95123, Italy.
Alfredo PulvirentiDepartment of Clinical and Experimental Medicine, Bioinformatics Unit, University of Catania, Catania 95123, Italy.
Veronica BalattiDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Laura RassentiDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Philip N TsichlisDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Thomas KippsDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Yuri PekarskyDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
Carlo M CroceDepartment of Cancer Biology and Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-3788-1457

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
NCI NIH HHS P30 CA016058NCI NIH HHS R35 CA197706
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most diagnosed forms of leukemia worldwide and it is usually classified into two forms: indolent and aggressive. These two forms are characterized by distinct molecular features that drive different responses to treatment and clinical outcomes. In this context, a better understanding of the molecular landscape of the CLL forms may potentially lead to the development of new drugs or the identification of novel biomarkers. Human endogenous retroviruses (HERVs) are a class of transposable elements that have been associated with the development of different human cancers, including different forms of leukemias. However, no studies about HERVs in CLL have ever been reported so far. Here, we present the first locus-specific profiling of HERV expression in both the aggressive and indolent forms of CLL. Our analyses revealed several dysregulations in HERV expression occurring in CLL and some of them were specific for either the aggressive or indolent form of CLL. Such results were also validated by analyzing an external cohort of CLL patients and by RT-qPCR. Moreover, in silico analyses have shown relevant signaling pathways associated with them suggesting a potential involvement of the dysregulated HERVs in these pathways and consequently in CLL development.

Indexed as

Endogenous RetrovirusesLeukemia, Lymphocytic, Chronic, B-CellBiomarkersHumansBiomarkersCLLHERVsRNA-Seq

Identifiers

PMID37871223
PMCPMC10622969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.